Session Type
CME accreditation
Date Time

The COVID-19 pandemic highlighted the potential role of monoclonal antibodies (mAbs) in tackling a leading infectious disease of global relevance; however, it also highlighted persistent challenges to mAbs access and impact related to emerging variants, high price, challenging administration requirements, and the lack of equitable global access. In the HIV space, the results from the Antibody Mediated Prevention trials provided proof of concept of the potential role of antibodies in HIV prevention, however, the AMP trials also underscored the need for combinations of antibodies that can prevent viral escape, potentially increasing known hurdles related to antibody cost and delivery. With an expanding HIV prevention pipeline and complexities in ensuring global access to mAbs, why should we remain excited about their important contribution to the HIV prevention toolbox? This session will bring together global experts and leaders to discuss innovations and emerging evidence to answer this critical question. The format will combine brief introductory comments from speakers on designated topics, as articulated below, to set the stage for a rich discussion on progress, potential challenges, and critical enablers of broad impact from the monoclonal antibodies.

3 min
Introductory notes on why we need to consider mAbs as a potential tool for HIV prevention
Shelly MALHOTRA, IAVI, United States
15 min
Can we design, develop and manufacture antibodies that are effective, affordable and easy to deliver? Evidence from the pipeline
Devin SOK, IAVI, United States
39 min
Panel discussion
Rachel BAGGALEY, World Health Organization, Switzerland
Lynda STRANIX-CHIBANDA, University of Zimbabwe, Zambia
Sharonann LYNCH, O'Neill Institute for National and Global Health Law, United States
Devin SOK, IAVI, United States
Carmen PÉREZ CASAS, Unitaid, Switzerland
Yvette RAPHAEL, APHA, South Africa
Shelly MALHOTRA, IAVI, United States
3 min
Closing remarks
Shelly MALHOTRA, IAVI, United States